Novo Nordisk Increasingly Calls Wegovy Users Customers, Months After FDA Flagged a 'Live Lighter' Pill Ad Claim
- On Wednesday, Novo Nordisk released OCTANE data showing users of oral Wegovy lost weight, while simultaneously labeling Wegovy users as "customers" rather than "patients" in marketing materials.
- Eight months after the FDA told Novo that a television ad for the pill was false or misleading, citing phrases like "live lighter," the company's strategic shift arrives.
- Data from the OCTANE study shows participants switching to the pill lost an average of 8.8 pounds over three months, with 40.7 percent achieving at least 5 percent weight loss.
- Martin Holst Lange, Novo's chief scientific officer, noted clear consumer preference for orals, stating the company aims to meet individuals "where they are" by facilitating treatment transitions.
- Separately, Novo announced on Wednesday that its experimental drug CagriSema reduced "food noise" and showed benefits for organ and bone health in adults with Type 2 diabetes.
27 Articles
27 Articles
Svenska Dagbladet
Pharmaceutical giant Novo is reducing the price of its weight loss drug Wegovy by 20 percent on the Swedish market. At the same time, the company is in the process of getting the drug subsidized.
Today, the price in Sweden of one of the most widely used obesity drugs – Wegovy – is being reduced by 20 percent. – We want more patients to be treated because the problem in Sweden is so big, says Jørgen Kronborg Jungersen, CEO of Novo Sweden. Here you will find more about medicine, health and research!
Patients lost an additional 4.1% in three months after switching from injectable weight loss medication to the oral Wigobi. Analysis of medical data from 194 patients showed an average weight loss of 4 kg from 100 kg. Research results indicate that patients who switched from injectable weight loss medication to the oral Wigobi continued their weight loss thereafter. Oral weight loss medication alleviates the burden associated with injections.
Patients who went from weight loss injections to New Nordisk's daily Wegovy tablet continued to lose weight, according to data reported at a medical conference today, while Danish pharmacist seeks to defend their li
Patients who replaced weekly injections for weight loss with the daily oral version of New Wegovy continued to lose body weight, according to clinical data released today during a medical conference. The results come at a time when the Danish pharmacist tries to consolidate her leadership over the US rival Eli Lilly in the growing market for oral treatments against obesity. The study participants lost an average of 4.1% of body weight over three…
Coverage Details
Bias Distribution
- 46% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
